View Item 

Show simple item record

Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials
dc.contributor.authorThanassoulis, George
dc.contributor.authorWilliams, Ken
dc.contributor.authorYe, Keying
dc.contributor.authorBrook, Robert
dc.contributor.authorCouture, Patrick
dc.contributor.authorLawler, Patrick R.
dc.contributor.authorGraaf, Jacqueline
dc.contributor.authorFurberg, Curt D.
dc.contributor.authorSniderman, Allan
dc.date.accessioned2017-11-13T16:40:30Z
dc.date.available2017-11-13T16:40:30Z
dc.date.issued2014-04
dc.identifier.citationThanassoulis, George; Williams, Ken; Ye, Keying; Brook, Robert; Couture, Patrick; Lawler, Patrick R.; Graaf, Jacqueline; Furberg, Curt D.; Sniderman, Allan (2014). "Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials." Journal of the American Heart Association (2): n/a-n/a.
dc.identifier.issn2047-9980
dc.identifier.issn2047-9980
dc.identifier.urihttps://hdl.handle.net/2027.42/139077
dc.publisherWiley
dc.subject.otherstatins
dc.subject.othernon‐HDL‐C
dc.subject.othermeta‐analysis
dc.subject.otherLDL‐C
dc.subject.otherapoB
dc.titleRelations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139077/1/jah3504-sup-0001-AppendixA-B.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139077/2/jah3504.pdf
dc.identifier.doi10.1161/JAHA.113.000759
dc.identifier.sourceJournal of the American Heart Association
dc.identifier.citedreferenceBruno G, Merletti F, Biggeri A, Bargero G, Prina‐Cerai S, Pagano G, Cavallo‐Perin P. Effect of age on the association of non‐high‐density‐lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study. Diabetologia. 2006; 49: 937 – 944.
dc.identifier.citedreferencePerk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33: 1635 – 1701.
dc.identifier.citedreferenceStone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd‐Jones DM, Blum CB, McBride P, Eckel RH, Schwartz JS, Goldberg AC, Shero ST, Gordon D, Smith SC Jr, Levy D, Watson K, Wilson PW. 2013. ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. pii: S0735‐1097(13)06028‐2. doi: 10.1016/j.jacc.2013.11.002.
dc.identifier.citedreferenceBoekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM Jr, Ridker PM, Kastelein JJ. Association of LDL cholesterol, non‐HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins. J Am Med Assoc. 2012; 307: 1302 – 1309.
dc.identifier.citedreferenceParish S, Offer A, Clarke R, Hopewell JC, Hill MR, Otvos JD, Armitage J, Collins R; Heart Protection Study Collaborative Group. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation. 2012; 125: 2469 – 2478.
dc.identifier.citedreferenceHeart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet. 2002; 360: 7 – 22.
dc.identifier.citedreferenceCholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta‐analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010; 376: 1670 – 1681.
dc.identifier.citedreferenceSniderman A, Thanassoulis G, Couture P, Williams K, Alam A, Furberg CD. Is lower and lower better and better? A re‐evaluation of the evidence from the CTT meta‐analysis for LDL lowering. J Clin Lipidol. 2012; 6: 427 – 433.
dc.identifier.citedreferenceRobinson JG, Wang S, Jacobson TA. Meta‐analysis of comparison of effectiveness of lowering apolipoprotein B versus low‐density lipoprotein cholesterol and non‐high‐density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol. 2012; 110: 1468 – 1476.
dc.identifier.citedreferencePedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyörälä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998; 97: 1453 – 1460.
dc.identifier.citedreferenceSimes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RAH. Relationship between lipid levels and clinical outcomes in the long‐term intervention with pravastatin in the ischemic disease (LIPID) trial. To what extent is the reduction in coronary events with pravastatin explained by on‐study lipid levels? Circulation. 2002; 105: 1162 – 1169.
dc.identifier.citedreferenceGotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S. Relation between baseline and on‐treatment lipid parameters and first acute major coronary events in the Air force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000; 101: 477 – 484.
dc.identifier.citedreferenceRidker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group. Reduction in C‐reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009; 373: 1175 – 1182.
dc.identifier.citedreferenceAmarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High‐dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355: 549 – 559.
dc.identifier.citedreferenceColhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton‐Menys V, Fuller JH; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo‐controlled trial. Lancet. 2004; 364: 685 – 696.
dc.identifier.citedreferenceThe Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low‐density lipoprotein cholesterol levels and low‐dose anticoagulation on obstructive changes in saphenous‐vein coronary‐artery bypass grafts. N Engl J Med. 1997; 336: 153 – 162.
dc.identifier.citedreferenceBorenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta‐Analysis. Chichester, UK: Wiley; 2009.
dc.identifier.citedreferenceNHANES dataset. http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/nhanes_analytic_guidelines_dec_2005.pdf. Accessed April 22, 2013.
dc.identifier.citedreferenceChien KL, Hsu HC, Su TC, Chen MF, Lee YT, Hu FB. Apolipoprotein B and non‐high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese. J Lipid Res. 2007; 48: 2499 – 2505.
dc.identifier.citedreferenceShai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, Stampfer MJ, Ma J. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation. 2004; 110: 2824 – 2830.
dc.identifier.citedreferenceBachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apolipoprotein B and AI distributions in the United States, 1988‐1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem. 1997; 43: 2364 – 2378.
dc.identifier.citedreferencePischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non‐high‐density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005; 112: 3375 – 3383.
dc.identifier.citedreferenceSniderman AD. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL lowering therapy: Implications for clinical practice. J Clin Lipidol. 2008; 2: 36 – 42.
dc.identifier.citedreferenceSniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta‐analysis of low‐density lipoprotein cholesterol, non‐high‐density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011; 4: 337 – 345.
dc.identifier.citedreferenceAwan Z, Seidah NG, MacFadyen JG, Benjannet S, Chasman DI, Ridker PM, Genest J. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem. 2012; 58: 183 – 189.
dc.identifier.citedreferenceSniderman AD, LaChapelle KJ, Rachon NA, Furberg CD. The necessity for clinical reasoning in the era of evidence‐based medicine. Mayo Clin Proc. 2013; 88: 1108 – 1114.
dc.identifier.citedreferenceAnderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, Genest J Jr, Carpentier AC, Dufour R, Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates GM, Stone JA, Ur E. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013; 29: 151 – 167.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jah3504-sup-0001-AppendixA-B.pdf
Size:
423.2KB
Format:
PDF
View/Open
Name:
jah3504.pdf
Size:
577.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.